Abstract
We recently developed a chimeric flavivirus vaccine technology based on the novel insect-specific Binjari virus (BinJV) and used this to generate a chimeric ZIKV vaccine (BinJ/ZIKA-prME) that protected IFNAR-/- dams and fetuses from infection. Herein, we show that a single vaccination of IFNAR-/- mice with unadjuvanted BinJ/ZIKA-prME generated neutralizing antibody responses that were retained for 14 months. At 15 months post vaccination, mice were also completely protected against detectable viremia and substantial body weight loss after challenge with ZIKVPRVABC59. BinJ/ZIKA-prME vaccination thus provided long-term protective immunity without the need for adjuvant or replication of the vaccine in the vaccine recipient, both attractive features for a ZIKV vaccine.
Highlights
Zika virus (ZIKV) is a mosquito-transmitted flavivirus and the etiological agent of congenital Zika syndrome (CZS), a constellation of primarily neurological birth defects that includes microcephaly [1,2]
We recently developed a chimeric flavivirus vaccine technology based on the insectspecific flavivirus, Binjari virus (BinJV)
We show that BinJ/ZIKA-pre-membrane and envelope (prME) was able to generate such immunity, with our previous studies showing that BinJ/ZIKA-prME has no detectable capacity to replicate in mammalian cells [12]
Summary
Zika virus (ZIKV) is a mosquito-transmitted flavivirus and the etiological agent of congenital Zika syndrome (CZS), a constellation of primarily neurological birth defects that includes microcephaly [1,2]. They might be viewed as a replication-defective virus-like-particle vaccine, which comprises the prME proteins of the target flavivirus, the capsid protein of BinJV, and the RNA of the chimeric virus [11,12]. Flavivirus vaccines utilizing the BinJV chimera technology have been shown to induce protective immunity in a number of pre-clinical models of infection and disease, including West Nile virus [13], dengue virus [14], ZIKV [12,15], and yellow fever virus [16]. In a new experiment, we extend our previous short-term immunity and protection studies [12,15] to illustrate that a single vaccination with the chimeric BinJV—ZIKV vaccine (BinJ/ZIKA-prME) provides long-term neutralizing antibody responses and protection against infection and diseases in female IFNAR-/- mice
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
